Sagimet Biosciences Inc. (以下简称“Sagimet”) 宣布，其最新研究进展将在“Fueling MASH：代谢驱动因素与炎症交互作用”Keystone研讨会上通过壁报和口头报告形式进行展示。此次会议将汇集该领域的顶尖专家，共同探讨代谢功能障碍相关脂肪性肝炎（MASH）的最新科学发现。
与此同时，公司还披露，已根据纳斯达克上市规则5635(c)(4)的规定，向新入职员工授予了一项诱导性股权奖励。此类奖励是生物技术公司常见的做法，旨在吸引高素质人才加盟，推动公司研发管线的进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.